Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study

Research output: Contribution to journalArticle

Abstract

The efficacy and safety of short-course intravenous (i.v.) antimicrobial therapy for bloodstream infections is unknown. Therefore, a retrospective 8-year cohort study including 1431 hospitalised adults was conducted to compare the outcomes of patients receiving short-course (5–10 days) and long-course (11–16 days) i.v. antibiotic therapy for community-onset bacteraemia. Of 1010 patients who received short-course therapy, 726 were matched with 363 patients in the long-course group through propensity score matching at a ratio of 1:2 based on independent predictors of 30-day mortality identified in the multivariate regression model. Following appropriate matching, similarities between the two groups in the proportion of baseline characteristics (age, sex, major co-morbidities, co-morbidity severity, bacteraemia severity at onset and major bacteraemia sources) and 30-day crude mortality rate after bacteraemia onset were observed. Notably, clinical outcomes within 30 days after the end of i.v. therapy, in terms of proportions of post-treatment overall infections (2.2% vs. 6.1%; P = 0.001), infections caused by antimicrobial-resistant pathogens (ARPs) (1.7% vs. 4.4%; P = 0.007), and thereby post-treatment crude mortality (1.4% vs. 3.6%; P = 0.009), were lower in the short-course group. In conclusion, for adults with community-onset uncomplicated bacteraemia, short-course (5–10 days) i.v. antibiotic treatment did not result in an increased risk of mortality but instead decreased the odds of overall and ARP infections after the treatment course.

Original languageEnglish
Pages (from-to)176-183
Number of pages8
JournalInternational journal of antimicrobial agents
Volume54
Issue number2
DOIs
Publication statusPublished - 2019 Aug 1

Fingerprint

Propensity Score
Bacteremia
Mortality
Therapeutics
Infection
Anti-Bacterial Agents
Morbidity
Sex Characteristics
Cohort Studies
Safety

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{87630e3cfcc7487691253cea62b56e3e,
title = "Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study",
abstract = "The efficacy and safety of short-course intravenous (i.v.) antimicrobial therapy for bloodstream infections is unknown. Therefore, a retrospective 8-year cohort study including 1431 hospitalised adults was conducted to compare the outcomes of patients receiving short-course (5–10 days) and long-course (11–16 days) i.v. antibiotic therapy for community-onset bacteraemia. Of 1010 patients who received short-course therapy, 726 were matched with 363 patients in the long-course group through propensity score matching at a ratio of 1:2 based on independent predictors of 30-day mortality identified in the multivariate regression model. Following appropriate matching, similarities between the two groups in the proportion of baseline characteristics (age, sex, major co-morbidities, co-morbidity severity, bacteraemia severity at onset and major bacteraemia sources) and 30-day crude mortality rate after bacteraemia onset were observed. Notably, clinical outcomes within 30 days after the end of i.v. therapy, in terms of proportions of post-treatment overall infections (2.2{\%} vs. 6.1{\%}; P = 0.001), infections caused by antimicrobial-resistant pathogens (ARPs) (1.7{\%} vs. 4.4{\%}; P = 0.007), and thereby post-treatment crude mortality (1.4{\%} vs. 3.6{\%}; P = 0.009), were lower in the short-course group. In conclusion, for adults with community-onset uncomplicated bacteraemia, short-course (5–10 days) i.v. antibiotic treatment did not result in an increased risk of mortality but instead decreased the odds of overall and ARP infections after the treatment course.",
author = "Lee, {Ching Chi} and Chih-Chia Hsieh and Chao-Yung Yang and Ming-Yuan Hong and Chung-Hsun Lee and Tang, {Hung Jen} and Wen-Chien Ko",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.ijantimicag.2019.05.014",
language = "English",
volume = "54",
pages = "176--183",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Short versus long duration antimicrobial treatment for community-onset bacteraemia

T2 - A propensity score matching study

AU - Lee, Ching Chi

AU - Hsieh, Chih-Chia

AU - Yang, Chao-Yung

AU - Hong, Ming-Yuan

AU - Lee, Chung-Hsun

AU - Tang, Hung Jen

AU - Ko, Wen-Chien

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The efficacy and safety of short-course intravenous (i.v.) antimicrobial therapy for bloodstream infections is unknown. Therefore, a retrospective 8-year cohort study including 1431 hospitalised adults was conducted to compare the outcomes of patients receiving short-course (5–10 days) and long-course (11–16 days) i.v. antibiotic therapy for community-onset bacteraemia. Of 1010 patients who received short-course therapy, 726 were matched with 363 patients in the long-course group through propensity score matching at a ratio of 1:2 based on independent predictors of 30-day mortality identified in the multivariate regression model. Following appropriate matching, similarities between the two groups in the proportion of baseline characteristics (age, sex, major co-morbidities, co-morbidity severity, bacteraemia severity at onset and major bacteraemia sources) and 30-day crude mortality rate after bacteraemia onset were observed. Notably, clinical outcomes within 30 days after the end of i.v. therapy, in terms of proportions of post-treatment overall infections (2.2% vs. 6.1%; P = 0.001), infections caused by antimicrobial-resistant pathogens (ARPs) (1.7% vs. 4.4%; P = 0.007), and thereby post-treatment crude mortality (1.4% vs. 3.6%; P = 0.009), were lower in the short-course group. In conclusion, for adults with community-onset uncomplicated bacteraemia, short-course (5–10 days) i.v. antibiotic treatment did not result in an increased risk of mortality but instead decreased the odds of overall and ARP infections after the treatment course.

AB - The efficacy and safety of short-course intravenous (i.v.) antimicrobial therapy for bloodstream infections is unknown. Therefore, a retrospective 8-year cohort study including 1431 hospitalised adults was conducted to compare the outcomes of patients receiving short-course (5–10 days) and long-course (11–16 days) i.v. antibiotic therapy for community-onset bacteraemia. Of 1010 patients who received short-course therapy, 726 were matched with 363 patients in the long-course group through propensity score matching at a ratio of 1:2 based on independent predictors of 30-day mortality identified in the multivariate regression model. Following appropriate matching, similarities between the two groups in the proportion of baseline characteristics (age, sex, major co-morbidities, co-morbidity severity, bacteraemia severity at onset and major bacteraemia sources) and 30-day crude mortality rate after bacteraemia onset were observed. Notably, clinical outcomes within 30 days after the end of i.v. therapy, in terms of proportions of post-treatment overall infections (2.2% vs. 6.1%; P = 0.001), infections caused by antimicrobial-resistant pathogens (ARPs) (1.7% vs. 4.4%; P = 0.007), and thereby post-treatment crude mortality (1.4% vs. 3.6%; P = 0.009), were lower in the short-course group. In conclusion, for adults with community-onset uncomplicated bacteraemia, short-course (5–10 days) i.v. antibiotic treatment did not result in an increased risk of mortality but instead decreased the odds of overall and ARP infections after the treatment course.

UR - http://www.scopus.com/inward/record.url?scp=85068358107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068358107&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2019.05.014

DO - 10.1016/j.ijantimicag.2019.05.014

M3 - Article

C2 - 31108223

AN - SCOPUS:85068358107

VL - 54

SP - 176

EP - 183

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -